Idhentify nct02577406
WebAbout IDHENTIFY. IDHENTIFY (NCT02577406) is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs), which include continuous 28-day cycles of best supportive care (BSC) only, azacitidine subcutaneously (SC) plus BSC, low-dose … Web13 nov. 2024 · IDHENTIFY : A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation Male or Female Status Closed (no longer …
Idhentify nct02577406
Did you know?
Web1 mrt. 2024 · A phase III study, known as IDHENTIFY, is comparing enasidenib with standard regimens in older patients with relapsed/refractory IDH2-mutant AML. ... (NCT02577406). Stein EM, DiNardo C, ... Web24 jun. 2024 · Dr Fathi talks on findings of the IDHENTIFY (AG-221-AML-004) study (NCT02577406) which assess the efficacy and safety of enasidenib (AG-221), an IDH2 inhibitor, versus conventional care regimens in patients with late stage AML.
Web1 okt. 2024 · Methods: IDHENTIFY (NCT02577406) enrolled patients aged ≥60 years who had received 2-3 prior AML-directed therapies. Patients were randomized 1:1 to enasidenib 100-mg/day or CCR (azacitidine, intermediate- or low-dose Ara-C, or supportive care). Co-occurring mutations were identified by targeted NGS of BMMC DNA. Web9 nov. 2024 · The multicenter, open-label, randomized, phase III study IDHENTIFY is currently recruiting elderly subjects ... (NCT02577406). The safety profiles of AG-120 and AG-221 in combination with standard induction and consolidation therapy are being currently investigated in a phase I study in patients with IDH-mutant AML ...
WebIDHENTIFY (NCT02577406) is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens … WebMethods: This open-label trial (NCT02577406) enrolled pts ≥ 60 years of age who had received 2 or 3 prior AML Tx. Pts were preselected to a CCR (azacitidine, intermediate- or low-dose Ara-C, or supportive care), and were then randomized 1:1 to ENA 100 mg/d or CCR in 28d cycles.
WebThe ongoing IDHENTIFY (ClinicalTrials.gov, NCT02577406) international, multicenter, phase 3 randomized, open-label trial is ongoing to compare the efficacy of enasidenib to conventional care (including best supportive care only, azacitidine subcutaneously plus best supportive care, low-dose cytarabine subcutaneously plus best supportive care, or …
Web1 okt. 2024 · Methods: IDHENTIFY (NCT02577406) enrolled patients aged ≥60 years who had received 2-3 prior AML-directed therapies. Patients were randomized 1:1 to … cholinergic and anticholinergic drugs mcqsWeb12 okt. 2016 · Both Celgene and Agios have incorporated this screening into clinical trial designs, including the recently initiated Phase 3 IDHENTIFY trial comparing enasidenib with conventional therapy in older patients with an IDH2 mutation and relapsed or refractory AML (NCT02577406). gray wash floating shelfWebMethods: IDHENTIFY (NCT02577406) enrolled patients aged ≥60 years who had received 2-3 prior AML-directed therapies. Patients were randomized 1:1 to enasidenib 100 … cholinergic and muscarinicWeb20 mrt. 2024 · ClinicalTrials.gov. An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY). NCT02577406. www.clinicaltrials.gov. Accessed December 21, 2016. cholinergic antagonist effectsWeb(IDHENTIFY, NCT02577406) vs. conventional care regimens (azacitadine, LoDAC) has been initiated in RR-AML IDH2 ... NCT02577406 AG-221IDH2 Agios/Celgene Ib Newly diagnosed, induction therapy and consolidation therapy NCT02632708 AG-881IDH1/2 Agios/Celgene***I Advanced, IDH1 and/or cholinergic and anticholinergic simplifiedWeb20 mei 2016 · NCT02577406). The IDHENTIFY protocol was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (91). A few clinical trials involving Enasidenib are still in the ... gray wash for hairWeb28 aug. 2024 · 这项名为idhentify (nct02577406)的3期 临床试验 比较了idhifa®与常规护理方案的疗效与安全性。 根据bms的公告显示，该试验并未达到主要终点——总体生存率（os），而安全性与先前报道的结果一致。 gray washing machie box